TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30673547

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (by pipelle biopsy)
Number of subjects: 1364

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 1364
Study: 30246016

Group type: EXPERIMENTAL
Intervention: Huaier (combined with sugar-free Yinxie granules and Huaiqihuang granules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (combined with sugar-free Yinxie granules)
Number of subjects: 0
Study: 26456162

Group type: EXPERIMENTAL
Intervention: Captopril (0.5%) cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diltiazem (2%) cream
Number of subjects: 50
Study: 24745802

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet applied directly to the skin
Number of subjects: 97
Study: 22061340

Group type: EXPERIMENTAL
Intervention: Parent-based intervention
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Peer-based intervention
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Parent and peer conditions
Number of subjects: 1275
Study: 18848480

Group type: EXPERIMENTAL
Intervention: ATS HOTV visual acuity protocol
Number of subjects: 142

Group type: COMPARATOR
Intervention: E-ETDRS visual acuity protocol
Number of subjects: 142
Study: 18161613

Group type: EXPERIMENTAL
Intervention: Reporting of key methodological items in RCTs
Number of subjects: 67
Study: 15896919

Group type: EXPERIMENTAL
Intervention: Clonidine challenge study for assessment of growth hormone release as a marker of tonic noradrenergic activation.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 90
Study: 12059915

Group type: EXPERIMENTAL
Intervention: Nickel‐titanium rotary instruments with additional apical enlargement to ISO size 35 (Group A, n = 16)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nickel‐titanium rotary instruments with no apical enlargement (Group B, n = 16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group with irrigation only (Group C, n = 6)
Number of subjects: 38
Study: 11167902

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8923354

Group type: EXPERIMENTAL
Intervention: DAB 486IL-2 at 0.075 mg/kg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study: 1442480

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single‐photon emission computed tomography (SPECT) thallium‐201 exercise scintigraphy
Number of subjects: 24
Study: 2578367

Group type: EXPERIMENTAL
Intervention: Warm bath (HOT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cool bath (COOL)
Number of subjects: 6
Study: 31368031

Group type: EXPERIMENTAL
Intervention: Exercise program 3 days/week for 3 months (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exercise-free (Group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy volunteers (Group C)
Number of subjects: 25
Study: 30145664

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25748452

Group type: EXPERIMENTAL
Intervention: Epidural Electrical Stimulation (EECS) during rehabilitation
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no EECS)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Investigational group (EECS)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Investigational patients with movement thresholds during stimulation testing
Number of subjects: 164
Study: 24559619

Group type: EXPERIMENTAL
Intervention: Finasteride (2.5 mg every 3 days for 6 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22159301

Group type: EXPERIMENTAL
Intervention: Maternal dietary counseling (home visits during the first year of life)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (data collection visits at 6 and 12 months)
Number of subjects: 100
Study: 20529205

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg once daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg once daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg and 4 mg once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Prucalopride (1-4 mg once daily)
Number of subjects: 300
Study: 18849320

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg once daily on days 1‐21) plus capecitabine (1,000 mg/m2 every 12 hours on days 1‐14) every 21 days
Number of subjects: 399

Group type: COMPARATOR
Intervention: Capecitabine alone (1,250 mg/m2 every 12 hours on days 1‐14) every 21 days
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 399

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 399
Study: 15640411

Group type: EXPERIMENTAL
Intervention: CO2 with small added amounts of ioxaglate (200 mgI/mL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Ioxaglate alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CO2 with small added amounts of ioxaglate
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study: 14686228

Group type: EXPERIMENTAL
Intervention: Prophylactic oral ganciclovir therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMV disease
Number of subjects: 0
Study: 10555883

Group type: EXPERIMENTAL
Intervention: CDP571 1 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CDP571 10 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8532768

Group type: EXPERIMENTAL
Intervention: 50 mM putrescine in a eutectic vehicle (Fibrostat) for 1 month
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham treatment for 1 month
Number of subjects: 43
Study: 1885075

Group type: EXPERIMENTAL
Intervention: 5-ASA 1 g enema
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 5-ASA 2 g enema
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 5-ASA 4 g enema
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 113
Study: 31621933

Group type: EXPERIMENTAL
Intervention: Edaravone (24-week treatment)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Edaravone (48-week treatment)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (24-week treatment followed by edaravone)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Edaravone (actual treatment)
Number of subjects: 123
Study: 30243949

Group type: EXPERIMENTAL
Intervention: Group-oriented integrative medicine approach combining dietary intervention and mind-body therapies followed by 8 weeks of telephonic health coaching
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group-oriented integrative medicine approach
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study: 27777436

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Number of subjects: 900

Group type: COMPARATOR
Intervention: 50 mg diclofenac suppository alone
Number of subjects: 900
Study: 25041058

Group type: EXPERIMENTAL
Intervention: MBSR (Mindfulness-Based Stress Reduction)
Number of subjects: 19
Study: 22311867

Group type: EXPERIMENTAL
Intervention: Any TIMI rated bleed
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Non-site access-related bleeds
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Site-access bleeds
Number of subjects: 744
Study: 20050717

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 80

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 80
Study: 18609189

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise (MI) for 2 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: High Intensity Exercise (HI) for 2 weeks
Number of subjects: 48
Study: 16024585

Group type: EXPERIMENTAL
Intervention: Almitrine 4 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM4+NO)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Almitrine 16 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM16+NO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12088576

Group type: EXPERIMENTAL
Intervention: Extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Concomitant administration of hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Number of subjects: 200
Study: 9831776

Group type: EXPERIMENTAL
Intervention: Increment analysis using DMFS increments
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Incidence density (ID) analysis
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Subjects lost to follow-up
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Loss to follow-up
Number of subjects: 1754
Study: 8523192

Group type: EXPERIMENTAL
Intervention: High-dose tyrosine supplementation (100 mg/kg body weight per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 24
Study: 1950390

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution and rehydration with albumin 20% and crystalloids
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: General intensive care treatment and monitoring with a pulmonary artery catheter
Number of subjects: 300
Study: 7134227

Group type: EXPERIMENTAL
Intervention: Influenza aluminium oxide adsorbate vaccine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Aqueous vaccine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 189
Study: 31696544

Group type: EXPERIMENTAL
Intervention: PUR1900 (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral Sporanox (200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PUR1900 (10-35 mg)
Number of subjects: 6
Study: 31668569

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-MSC treatment (prednisone and azithromycin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (MSCs and non-MSCs)
Number of subjects: 81
Study: 29929873

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26307163

Group type: EXPERIMENTAL
Intervention: Wolf Piranha
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lumenis VersaCut
Number of subjects: 74
Study: 24814090

Group type: EXPERIMENTAL
Intervention: Etrolizumab 100 mg (subcutaneous at weeks 0, 4, and 8, with placebo at week 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Etrolizumab 300 mg plus loading dose (420 mg at week 0, followed by 300 mg at weeks 2, 4, and 8)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Etrolizumab 100 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Etrolizumab 300 mg plus loading dose
Number of subjects: 124
Study: 22266332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel and placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel and an aromatase inhibitor
Number of subjects: 21
Study: 19468278

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (2 mg/kg/h)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 48
Study: 17346020

Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation and Prontosan gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (implied control)
Number of subjects: 10
Study: 14640988

Group type: EXPERIMENTAL
Intervention: +ATD
Number of subjects: 149

Group type: COMPARATOR
Intervention: -ATD
Number of subjects: 149
Study: 10960374

Group type: EXPERIMENTAL
Intervention: Wide pad support width (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Narrow pad support width (Group 1)
Number of subjects: 40
Study: 8798100

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1474161

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine combined with Ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.08 mg, 0.1 mg, and 0.2 mg; Promethazine 12.5 mg and 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline, 1 mL)
Number of subjects: 0
Study: 6372084

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg suppositories
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oxyphenbutazone 250 mg suppositories
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 31927346

Group type: EXPERIMENTAL
Intervention: Yoga (12 supervised weekly sessions)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Written self-care advice (control)
Number of subjects: 77
Study: 31870303

Group type: EXPERIMENTAL
Intervention: Target SNP-seq genotyping method using a panel of 92 perfect SNPs
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: KASPar markers (35 core SNPs)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: STRUCTURE clustering
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Nine loci on chromosomes 1, 2, 3, 4, 6, and 12
Number of subjects: 271
Study: 27936818

Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Comparison control conditions
Number of subjects: 610
Study: 26065866

Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (MRV) with gadofosveset trisodium (0.03 mmol/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Direct thrombus imaging (DTHI) without contrast agent
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of MRV and DTHI
Number of subjects: 10
Study: 23301632

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117

Group type: COMPARATOR
Intervention: Overall mortality and other malignancies
Number of subjects: 3117
Study: 21658561

Group type: EXPERIMENTAL
Intervention: CABG + BMMNC
Number of subjects: 60

Group type: COMPARATOR
Intervention: CABG only (placebo-control)
Number of subjects: 60
Study: 19503764

Group type: EXPERIMENTAL
Intervention: N-Acetylcarnosine (1% NAC) eye drops administered topically for 9 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo eye drops administered topically for 9 months
Number of subjects: 75
Study: 16995328

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea tincture (4 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea tablets (12 tablets)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (both preparations)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14972468

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) - 20-Hz square waves at a 300-microsecond pulse duration for 15 minutes twice daily for 1 month.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Extracorporeal Magnetic Innervation (ExMI) - Neocontrol system, 20 minutes twice a week for 2 months, with pulse frequencies of 10 Hz and 50 Hz.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group - Pelvic floor muscle exercises only.
Number of subjects: 36
Study: 11795386

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study: 9551748

Group type: EXPERIMENTAL
Intervention: PAV (8.6+/‐3.6 cmH2O x L(‐1) and 3+/‐1.3 cmH2O x L(‐1)x s(‐1) of volume and flow assistance, EPAP: 1 cmH2O)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PSV (inspiratory pressure support: 12‐16 cmH2O; EPAP: 1 cmH2O)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPAP (6 cmH2O)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham ventilation (CPAP: 1 cmH2O)
Number of subjects: 15
Study: 8068939

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses of 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses starting from 2.5 micrograms/kg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at doses of 10 and 20 micrograms/kg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6)
Number of subjects: 20
Study: 3174723

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (80 mg/daily) for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline) for 5 days
Number of subjects: 20
Study: 30314560

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) intervention including clinical coaching by a gerontology nurse specialist (GNS) and a review of selected high-risk residents' care-plans.
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Sensitivity model using a shorter, staggered time period for intervention effect testing.
Number of subjects: 1296
Study: 27631544

Group type: EXPERIMENTAL
Intervention: Combo (tracksuit jacket with integrated heating elements and dry land-based exercise routine)
Number of subjects: 25
Study: 25439611

Group type: EXPERIMENTAL
Intervention: Cornea from a donor with diabetes
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Cornea from a donor without diabetes
Number of subjects: 1090
Study: 24156389

Group type: EXPERIMENTAL
Intervention: Calcium and magnesium (1g Ca Gluconate plus 1g MgSO4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 20
Study: 21130349

Group type: EXPERIMENTAL
Intervention: Knowledge translation (KT) interventions
Number of subjects: 0
Study: 18323507

Group type: EXPERIMENTAL
Intervention: Automated tissue segmentation protocol with lesion segmentation
Number of subjects: 59
Study: 16551359

Group type: EXPERIMENTAL
Intervention: Severity index for patients with aortic sclerosis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Severity index for patients with mild to moderate AS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Severity index for patients with severe AS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aortic jet velocity by echocardiography
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Square root of the maximum aortic valve gradient by cardiac catheterization
Number of subjects: 48
Study: 14972007

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 45
Study: 10931080

Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075 mg/day to 0.6 mg once daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg/week to 1.5 mg twice weekly)
Number of subjects: 39
Study: 9294797

Group type: EXPERIMENTAL
Intervention: Cancellous screws
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sliding hip screw (SHS) and derotation screw (DRS) composite
Number of subjects: 0
Study: 8362999

Group type: EXPERIMENTAL
Intervention: Combined curriculum
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Curricula teaching refusal skills
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Curricula correcting social misperceptions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single programs
Number of subjects: 48
Study: 2823841

Group type: EXPERIMENTAL
Intervention: 1500 IU low molecular weight heparin (LMWH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2000 IU low molecular weight heparin (LMWH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2500 IU low molecular weight heparin (LMWH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5000 IU unfractionated heparin
Number of subjects: 8
Study: 30288474

Group type: EXPERIMENTAL
Intervention: Maralixibat 70 µg/kg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maralixibat 140 µg/kg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maralixibat 280 µg/kg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All doses of maralixibat combined
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maralixibat (any dose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 28355577

Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training task
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo task
Number of subjects: 70
Study: 23575004

Group type: EXPERIMENTAL
Intervention: Bone wax
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 184
Study: 22257756

Group type: EXPERIMENTAL
Intervention: LigaSure Precise™ vessel sealing system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional suture ligatures
Number of subjects: 40
Study: 19175784

Group type: EXPERIMENTAL
Intervention: Eosin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Topical Steroids
Number of subjects: 43
Study: 17595435

Group type: EXPERIMENTAL
Intervention: Parenteral amino acids at 1.5 g/kg/d for >24 hours
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Parenteral amino acids at 3 g/kg/d for short (5 hours), extended (24 hours), or prolonged (3-5 days) duration
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infants with large patent ductus arteriosus (PDA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gestational age, weight loss, and patent ductus arteriosus
Number of subjects: 122
Study: 16306548

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12666487

Group type: EXPERIMENTAL
Intervention: PDSII loop suture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous suture with Vicryl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical suture by individual silone stitches
Number of subjects: 0
Study: 10480960

Group type: EXPERIMENTAL
Intervention: Pressure reducing foam mattresses (PRFMs)
Number of subjects: 18